Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ZEN003694 + Enzalutamide in mCRPC
NCT04986423Phase 2Recruiting
- Sponsor
- Zenith Epigenetics
- Start
- Sep 2021
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 2 trial of ZEN3694 in metastatic castration-resistant prostate cancer (mCRPC), sponsored by Zenith Epigenetics. Started Sep 2021; status: recruiting.
02
Drugs
ZEN3694
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT04986423.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04986423.